Every population outside Africa descends from a subset of African genetic diversity. That single fact, well established in population genetics, means Africa holds more human genetic variation than any other continent on Earth. And yet African populations account for a strikingly small share of the genomic data driving global research, diagnostics, and drug development, generally estimated at under three percent.
This is not a purely academic imbalance. Genomic reference databases inform how genetic test results are interpreted, which variants are flagged as disease-causing, and how medications are dosed. When those databases are built overwhelmingly from European and East Asian populations, diagnostic tools and treatment guidelines carry blind spots for African patients, sometimes misclassifying harmless genetic variation as dangerous, or missing risk factors entirely.
Closing this gap requires more than good intentions. It requires African-led research institutions generating African genomic data, on African terms, for the direct benefit of African patients, rather than simply serving as data collection sites for research agendas set elsewhere.
This is the thinking behind Centre-GPMI's research strategy. Every pilot program we run, from genomic literacy campaigns to sickle cell screening, is designed not only to deliver an immediate health benefit, but to build toward a future where biobanking, pharmacogenomic profiling, and large-scale genomic studies are things Africa does for itself, with its own institutions, its own researchers, and its own populations represented at every stage.